Dear Editor,

A 61-year-old woman with IgM-monoclonal gammopathy of unknown significance (MGUS) type lambda was transferred to our department in October 2018 showing a severe nephrotic syndrome. Renal function was not impaired. Due to a common variable immunodeficiency (CVID) syndrome with hypogammaglobulinemia (IgA and IgG), the patient received polyvalent human IVIGs in a dose of 20 g every 3 to 4 weeks since 2014. The immunoglobulin preparation used (Privigen®, CSL Behring GmbH, Germany) contains IgG1 67.8%, IgG2 28.7%, IgG3 2.3%, IgG4 1.2% and IgA at a maximum of 25 μg/mL, 250 mmol/L L-proline and water [1].

Current findings showed reduced complement factors (C3: 0.41 g/L [NR: 0.78–1.51 g/L]; C4: 0.11 g/L [NR: 0.12–0.33 g/L]) suggesting an immunocomplex-mediated disease. ANA, ds-DNA, cryoglobulins, p- and c-ANCA-antibodies were normal. Serologies for HIV, hepatitis B and C were negative. Ultrasound diagnostics and chest x-ray showed pulmonary and hepatic congestion. Echocardiography was normal. Diuretic treatment was initiated, leading to adequate weight loss. Renal biopsy was performed. Findings were compatible with a membranoproliferative glomerulonephritis (MPGN) of the immune complex type with deposits of IgM matching the serological findings of the paraproteinemia [2]. Repeated bone marrow biopsy excluded again Waldenström macroglobulinemia, myeloma or other hematological malignancy, a CT-scan ruled out osteolysis.

The preexisting high-risk IgM-MGUS was updated to that of IgM-MGRS [3–5]. Assuming a potential effect of the IVIGs on the development of MPGN, they were discontinued. In fact, serum levels of IgM spontaneously dropped rapidly and nearly normalized within 23 weeks (17.3 g/L to 3.65 g/L; NR: 0.46–2.92 g/L) as well as serum free light chains (sFLC) lambda (540 mg/L to 68 mg/L; NR: < 26.3 mg/L) and proteinuria (20 g/gCrea to 0.9 g/gCrea; NR: < 0.1 g/gCrea) (Fig. 1). In parallel, IgG levels decreased as expected after cessation of the IVIG therapy. Therefore, IVIG therapy was reintroduced in reduced dosage (10 g) and prolonged time interval (4 weeks). Following this regime, the patient had no episode of infection whilst having a further decreasing proteinuria (0.49 g/gCrea in July 2019).

Surprisingly, not only nephrological but also hematological results improved enormously to a point that neither criteria for MGRS nor even MGUS were fulfilled [6].

The parallel decrease of IgM, sFLC-lambda and proteinuria suggests a potential role for IVIGs in the pathogenesis of MGUS and the resulting IgM-positive MPGN in this patient. A direct effect of IVIGs is unlikely as the IVIG preparation used was free of IgM. However, IVIGs are known to also contain natural auto-antibodies including IgM type auto-antibodies [7]. In addition, idiotypic receptors on plasma cells secreting IgM may be activated by anti-idiotypic antibodies in the IVIG preparation resulting in stimulated IgM synthesis [8].

We speculate that IVIGs induced an acute immune response leading to monoclonal IgM production followed by its renal deposition causing glomerular immune reactions. To our knowledge, this is the first case describing a reversible high-risk MGUS and MGUS-associated immune complex-
mediated MPGN provoked by the administration of IVIGs. Yet, the precise immune mechanisms underlying this observation remain unclear.

**Funding information** Open Access funding provided by Projekt DEAL.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. (2017) Prescribing information Privigen 100mg/ml infusion solution CSL Behring
2. Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis—a new look at an old entity. N Engl J Med 366(12):1119–1131
3. Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Naar SH, on behalf of the International Kidney and Monoclonal Gammopathy Research Group (2015) Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87(4):698–711
4. Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, Merlini G (2018) Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 132(14):1478–1485
5. Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A, Leung N (2013) How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 122(22):3583–3590
6. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346(8):564–569
7. Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y (2009) Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol 158(Suppl 1):43–50
8. Golub ES (1980) Idiotypes and the network hypothesis. Cell. 22(3):641–642

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.